Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 December 2021 | Story Michelle Nothling | Photo Supplied
Lentsu Nchabeleng
Dr Ntheno Nchabeleng was appointed as the Deputy Director in the Gender and Anti-Discrimination Office within the Unit for Institutional Change and Social Justice.

A total of 10 006 rape cases were reported between April and June 2021. This is according to the latest SA crime statistics for the first quarter of 2021/2022. From a sample of 5 439 of these rape cases, 3 766 of incidents took place in the victim’s home or that of the rapist. A shadow pandemic of gender-based violence against our women and children is raging in South Africa.

It is within this global and local context that the Gender and Anti-Discrimination Office (GEADO) at the university is making inroads into supporting survivors of gender-based violence (GBV) and changing gender stereotypes.

GEADO in focus

GEADO is situated within the Unit for Institutional Change and Social Justice on the Bloemfontein Campus. It is mandated to deal with incidents of unfair discrimination and GBV as it relates to the UFS community, and to conduct advocacy and training in these areas. Deputy Director of GEADO, Dr Ntheno Nchabeleng, explains that “through high-impact practices and interventions, the Office works to systematically reduce case attrition to ensure that all reports and cases follow procedurally just processes”.

GEADO has been established at all the UFS campuses with well-trained and fully equipped Senior Gender Officers leading each. Geraldine Langau—supported by research assistant Delisile Mngadi—is managing the office at the Bloemfontein Campus, Chelepe Mocwana the Qwaqwa Campus, and Sivuyisiwe Magayana oversees the South Campus office.

Addressing gender-based violence

Prevention and response to GBV are at the core of GEADO’s work. With our country wracked by sexual violence and femicide, “it has become a nightmare to be a woman in South Africa”, Dr Nchabeleng says.

Its preventative efforts focus on the underlying causes of GBV to transform patriarchal notions, misogynistic norms, power imbalances, and toxic gender stereotypes. Fostering collaboration with various strategic partners to strengthen its impact, GEADO recently started working with Amnesty International Sub-Saharan Africa and Amnesty International Latin America to spread awareness on various forms of violence experienced by vulnerable populations. GEADO has also partnered with other local stakeholders in an effort to eradicate GBV through programming that includes awareness campaigns, online mobilisation, training, and webinars.

Becoming part of the solution

“Become change agents,” Dr Nchabeleng urges. One way to start shifting attitudes and mindsets is to change the way we speak. Examples would be to refrain from sexist and discriminatory language and phrases that undermine and degrade our women. Gendered name-calling generally depicts women and girls as inferior and less than fully human. Another area of concern is the way young people — especially young men — engage in disparaging conversations about women on social media platforms. This behaviour needs to cease. As a society, we also need to stop victim blaming, stop normalising rape culture, and stop entertaining sexual violence jokes,” Dr Nchabeleng says.

These changes start with each of us.

Incidents of GBV and discrimination can be reported to GEADO at:
Bloemfontein Campus: +27 51 401 3982
South Campus: +27 51 401 7544
Qwaqwa Campus: +27 58 718 5431

Sexual Assault Response Team (SART):
www.ufs.ac.za/sart 
Toll-free number +27 80 020 4682

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept